Bipolar Depression Drug Trial Results Have Been Presented

Autobahn Therapeutics shared positive Phase 2 findings for its new adjunctive treatment, elunetirom.

Updated on Sept. 21, 2026 in Mental Health

Isometric editorial illustration of a sculptural crystalline neuro-biological structure on a clinical plinth, representing progress in neurological health research. — Autobahn Therapeutics announced positive Phase 2 clinical trial results for elunetirom, a new adjunctive treatment for adults with bipolar depression. AI Illustration. Upload story photo >

Live Poll

Do you trust that new pharmaceutical breakthroughs effectively improve long-term daily functioning for mental health patients?

Autobahn Therapeutics presented full Phase 2 AMPLIFY-BD trial results, showing that elunetirom effectively treated bipolar depression in adult patients. The medication was administered as an adjunctive treatment alongside existing mood stabilizers or antipsychotic regimens.

Why it matters

The study sought to evaluate the efficacy and safety of elunetirom for the approximately 7 million U.S. adults living with bipolar depression. Researchers hope the drug improves mitochondrial health and neuroplasticity by targeting CNS thyroid hormone receptors.

The trial of 21 participants reported a 75 percent response rate and a 50 percent remission rate at Week 6. Common treatment-related adverse events included dizziness, diarrhea, and decreased free thyroxine.

The players

Autobahn Therapeutics

This is a biotechnology company focused on developing therapies that target the central nervous system to treat psychiatric and neurological conditions.

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.

The details

Patients in the study received a 2.8 microgram oral dose of elunetirom daily for six weeks while continuing their primary mood stabilizer or antipsychotic medication. The primary endpoint measured changes in HAMD-17 total scores, which showed steady improvement throughout the trial period.

September 15-19, 2026: Psych Congress 2026 took place in New Orleans.
Week 2: Patients showed a 9.7 point mean reduction in HAMD-17 scores.
Week 4: Patients showed a 13.7 point mean reduction in HAMD-17 scores.
Week 6: The trial reached its primary endpoint with a 16.8 point HAMD-17 reduction.

The Big Picture

This development follows the established FDA Fast Track designation process, which is designed to facilitate the development of drugs that treat serious conditions. It highlights the ongoing scientific effort to find novel adjunctive therapies that improve mitochondrial health and neuroplasticity.

This trial offers hope for new treatment options for those currently using mood stabilizers or antipsychotics who seek additional relief. While the results are promising, patients should consult their doctors regarding any potential side effects like dizziness or gastrointestinal issues.

The takeaway

The successful Phase 2 results for elunetirom provide a potential new avenue for managing bipolar depression as an adjunctive therapy. Patients should continue working closely with their healthcare providers to monitor their current treatment regimen and discuss emerging clinical developments.